Hosted on MSN

BeOne Medicines advances early cancer trial for BG-75098, signaling steady pipeline progress

BeOne Medicines (ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early-stage trial to test a new cancer drug, BG-75098, in adults with advanced solid tumors.
Seeking Alpha

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare ...
GEN

Sanofi to Acquire Blueprint Medicines for Up to $9.5B

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an ...
STAT

Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. On Wednesday, scientists reported interim results from an early study of ...
Fox 5 San Diego

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...